市场快照
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| CAGR: | 10.2 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
由于癌症患病率的上升、政府提高癌症意识的举措以及患者援助计划 (PAP) 的增加，预计亚太癌症治疗市场将出现良好增长。
肺癌、胃癌、结肠直肠癌、肝癌和食道癌是中国最常见的癌症类型。癌症负担和癌症治疗的日益流行是由许多因素造成的，包括人口增长、老龄化、环境污染和不健康的饮食习惯。此外，特别是吸烟，在亚太地区也继续盛行。因此，癌症患病率的上升有助于市场在预测期内增长。
报告范围
根据报告的范围，癌症疗法是通过干扰参与癌细胞生长或扩增的特定分子（如 DNA 或蛋白质）来阻止癌症生长和增殖的药物。这些疗法包括手术、放射疗法、化学疗法、免疫疗法等。
| By Treatment Type | |
| Chemotherapy | |
| Target Therapy | |
| Immunotherapy | |
| Hormone Therapy | |
| Other Treatment Types |
| By Cancer Type | |
| Blood Cancer | |
| Breast Cancer | |
| Prostate Cancer | |
| Gastrointestinal Cancer | |
| Gynecologic Cancer | |
| Respiratory/Lung Cancer | |
| Other Cancer Types |
| By End User | |
| Hospitals | |
| Specialty Clinics | |
| Radiation Therapy Center |
| Geography | ||||||||
|
主要市场趋势
靶向治疗有望在预测期内显示出良好的增长
预计目标治疗部分将在预测期内显示出良好的复合年增长率。靶向疗法包括激素疗法、基因表达调节剂、细胞凋亡诱导剂、血管生成抑制剂、免疫疗法、信号转导抑制剂和毒素递送分子。靶向治疗因其对癌细胞的特异性而变得越来越重要，同时对脱靶细胞没有毒性。
推动该细分市场增长的其他主要因素是研发的增加和全球各种癌症患病率的上升。靶向治疗是一种治疗癌症的方法，与用于癌症的传统化学疗法不同。靶向治疗药物通过靶向癌细胞中存在的特定基因或蛋白质来发挥作用。
To understand key trends, Download Sample Report
竞争格局
癌症治疗市场竞争激烈，由多个参与者组成。就市场份额而言，目前很少有主要参与者主导市场。然而，随着技术进步和产品创新，中小型公司正在通过以更便宜的价格推出新产品来增加其市场占有率。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Prevalence of Cancer
-
4.2.2 Growing Government Initiatives for Cancer Awareness
-
4.2.3 Increasing Patient Assistance Programs (PAPs)
-
-
4.3 Market Restraints
-
4.3.1 High Cost of Cancer Therapies
-
4.3.2 Fluctuation in Reimbursement Policies
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Treatment Type
-
5.1.1 Chemotherapy
-
5.1.2 Target Therapy
-
5.1.3 Immunotherapy
-
5.1.4 Hormone Therapy
-
5.1.5 Other Treatment Types
-
-
5.2 By Cancer Type
-
5.2.1 Blood Cancer
-
5.2.2 Breast Cancer
-
5.2.3 Prostate Cancer
-
5.2.4 Gastrointestinal Cancer
-
5.2.5 Gynecologic Cancer
-
5.2.6 Respiratory/Lung Cancer
-
5.2.7 Other Cancer Types
-
-
5.3 By End User
-
5.3.1 Hospitals
-
5.3.2 Specialty Clinics
-
5.3.3 Radiation Therapy Center
-
-
5.4 Geography
-
5.4.1 Asia-Pacific
-
5.4.1.1 China
-
5.4.1.2 Japan
-
5.4.1.3 India
-
5.4.1.4 Australia
-
5.4.1.5 South Korea
-
5.4.1.6 Rest of Asia-Pacific
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Amgen
-
6.1.2 AstraZeneca
-
6.1.3 Bayer AG
-
6.1.4 Bristol Myers Squibb Company
-
6.1.5 F. Hoffman-La Roche Ltd
-
6.1.6 Johnson & Johnson
-
6.1.7 Merck & Co. Inc.
-
6.1.8 Eli Lilly and Company
-
6.1.9 Novartis AG
-
6.1.10 Pfizer Inc.
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Asia-Pacific Cancer Therapy Market market is studied from 2018 - 2026.
What is the growth rate of Asia-Pacific Cancer Therapy Market?
The Asia-Pacific Cancer Therapy Market is growing at a CAGR of 10.2% over the next 5 years.
Who are the key players in Asia-Pacific Cancer Therapy Market?
Amgen, Astra Zeneca, Bayer AG, Johnson & Johnson, Merck & Co. Inc. are the major companies operating in Asia-Pacific Cancer Therapy Market.
